• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Evolving treatment strategies in CML - moving from early and deep molecular responses to TKI discontinuation and treatment-free remission: is there a need for longer-term trial outcomes?

作者信息

Eşkazan Ahmet Emre

机构信息

Division of Hematology, Department of Internal Medicine, Cerrahpasa Faculty of Medicine, Istanbul University, Istanbul, Turkey.

出版信息

Br J Clin Pharmacol. 2018 Aug;84(8):1635-1638. doi: 10.1111/bcp.13637. Epub 2018 Jun 3.

DOI:10.1111/bcp.13637
PMID:29862545
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6046500/
Abstract
摘要

相似文献

1
Evolving treatment strategies in CML - moving from early and deep molecular responses to TKI discontinuation and treatment-free remission: is there a need for longer-term trial outcomes?慢性粒细胞白血病不断演变的治疗策略——从早期深度分子反应到酪氨酸激酶抑制剂停药和无治疗缓解：是否需要长期试验结果？
Br J Clin Pharmacol. 2018 Aug;84(8):1635-1638. doi: 10.1111/bcp.13637. Epub 2018 Jun 3.
2
Discontinuing Tyrosine Kinase Inhibitor Therapy in Chronic Myelogenous Leukemia: Current Understanding and Future Directions.慢性粒细胞白血病中酪氨酸激酶抑制剂治疗的停药：当前认识与未来方向
Clin Lymphoma Myeloma Leuk. 2016 Sep;16(9):488-494. doi: 10.1016/j.clml.2016.06.012. Epub 2016 Jun 16.
3
Current Information and Recommendations on the Discontinuation of TKI Inhibitors in Chronic Myeloid Leukemia.慢性髓性白血病中酪氨酸激酶抑制剂停药的最新信息和建议。
Curr Oncol Rep. 2018 Mar 6;20(3):23. doi: 10.1007/s11912-018-0669-y.
4
Response to Therapy, Treatment Intolerance and Tyrosine Kinase Inhibitor Cessation Eligibility in a Real-World Cohort of Chronic Myeloid Leukaemia Patients.慢性髓性白血病患者真实世界队列中对治疗的反应、治疗不耐受及酪氨酸激酶抑制剂停药资格
Ulster Med J. 2019 May;88(2):105-110. Epub 2019 Apr 27.
5
The concept of treatment-free remission in chronic myeloid leukemia.慢性髓性白血病中无治疗缓解的概念。
Leukemia. 2016 Aug;30(8):1638-47. doi: 10.1038/leu.2016.115. Epub 2016 May 2.
6
Tyrosine-kinase inhibitor discontinuation in chronic myeloid leukaemia after deep molecular response: a meta-analysis with meta-regression.慢性髓性白血病深度分子反应后酪氨酸激酶抑制剂停药：一项包含Meta回归的Meta分析
J Chemother. 2020 Sep;32(5):268-271. doi: 10.1080/1120009X.2020.1716492. Epub 2020 Jan 25.
7
Dasatinib: a tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia.达沙替尼：一种用于治疗慢性粒细胞白血病和费城染色体阳性急性淋巴细胞白血病的酪氨酸激酶抑制剂。
Clin Ther. 2007 Nov;29(11):2289-308. doi: 10.1016/j.clinthera.2007.11.005.
8
Second tyrosine kinase inhibitor discontinuation attempt in patients with chronic myeloid leukemia.慢性髓性白血病患者停用第二种酪氨酸激酶抑制剂的尝试
Cancer. 2017 Nov 15;123(22):4403-4410. doi: 10.1002/cncr.30885. Epub 2017 Jul 25.
9
Sudden blastic transformation in treatment-free remission chronic myeloid leukaemia.未经治疗缓解的慢性髓性白血病中的急性原始细胞转化
Br J Haematol. 2019 Nov;187(4):543-545. doi: 10.1111/bjh.16245. Epub 2019 Oct 4.
10
Discontinuation of tyrosine kinase inhibitors in chronic myeloid leukemia: Recommendations for clinical practice from the French Chronic Myeloid Leukemia Study Group.酪氨酸激酶抑制剂在慢性髓性白血病中的停药：法国慢性髓性白血病研究组的临床实践建议。
Cancer. 2018 Jul 15;124(14):2956-2963. doi: 10.1002/cncr.31411. Epub 2018 May 3.

引用本文的文献

1
Chronic myeloid leukemia with a significant increase of monocytes and rare karyotype: A case report and literature review.伴有单核细胞显著增多和罕见核型的慢性髓细胞白血病：一例病例报告及文献复习。
Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2021 Mar 28;46(3):322-327. doi: 10.11817/j.issn.1672-7347.2021.200273.
2
Tyrosine Kinase Inhibitor Sequencing in Patients with Chronic Myeloid Leukemia.慢性髓性白血病患者的酪氨酸激酶抑制剂测序
Oncol Ther. 2019 Dec;7(2):95-100. doi: 10.1007/s40487-019-00098-w. Epub 2019 Aug 8.
3
Chronic myeloid leukaemia and the use of tyrosine kinase inhibitors in the days of COVID-19 pandemic.慢性髓性白血病与新冠疫情期间酪氨酸激酶抑制剂的使用
Br J Clin Pharmacol. 2020 Sep;86(9):1790-1792. doi: 10.1111/bcp.14353. Epub 2020 May 20.
4
Tyrosine kinase inhibitors (TKIs) used in the management of chronic myeloid leukaemia are associated with haematologic toxicities-Which TKI is the safest?用于治疗慢性髓性白血病的酪氨酸激酶抑制剂（TKIs）与血液学毒性相关 - 哪种TKI最安全？
Br J Clin Pharmacol. 2019 Oct;85(10):2241-2243. doi: 10.1111/bcp.14092. Epub 2019 Aug 22.

本文引用的文献

1
When to Stop Tyrosine Kinase Inhibitors for the Treatment of Chronic Myeloid Leukemia.何时停止酪氨酸激酶抑制剂治疗慢性髓性白血病。
Curr Treat Options Oncol. 2018 Mar 8;19(3):15. doi: 10.1007/s11864-018-0532-2.
2
Treatment-Free Remission After Second-Line Nilotinib Treatment in Patients With Chronic Myeloid Leukemia in Chronic Phase: Results From a Single-Group, Phase 2, Open-Label Study.二线尼洛替尼治疗后慢性髓性白血病慢性期患者无治疗缓解：单组、2 期、开放标签研究结果。
Ann Intern Med. 2018 Apr 3;168(7):461-470. doi: 10.7326/M17-1094. Epub 2018 Feb 20.
3
Considerations for Successful Treatment-free Remission in Chronic Myeloid Leukemia.慢性髓性白血病无治疗缓解的成功治疗考量
Clin Lymphoma Myeloma Leuk. 2018 Feb;18(2):98-105. doi: 10.1016/j.clml.2017.11.006. Epub 2017 Nov 29.
4
The IUPHAR/BPS Guide to PHARMACOLOGY in 2018: updates and expansion to encompass the new guide to IMMUNOPHARMACOLOGY.2018 年 IUPHAR/BPS 药理学指南：更新和扩展，以包含新的免疫药理学指南。
Nucleic Acids Res. 2018 Jan 4;46(D1):D1091-D1106. doi: 10.1093/nar/gkx1121.
5
Bosutinib Versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia: Results From the Randomized BFORE Trial.博舒替尼对比伊马替尼用于新诊断的慢性髓性白血病：随机 BFORE 试验结果。
J Clin Oncol. 2018 Jan 20;36(3):231-237. doi: 10.1200/JCO.2017.74.7162. Epub 2017 Nov 1.
6
How I manage relapse of chronic myeloid leukaemia after stopping tyrosine kinase inhibitor therapy.酪氨酸激酶抑制剂治疗停药后，我如何处理慢性髓性白血病复发问题。
Br J Haematol. 2018 Jan;180(1):24-32. doi: 10.1111/bjh.14973. Epub 2017 Oct 19.
7
Tyrosine kinase inhibitor (TKI) therapy for newly-diagnosed patients with chronic myeloid leukemia: focusing on TKI discontinuation due to adverse events - is better always good?酪氨酸激酶抑制剂（TKI）用于新诊断慢性髓性白血病患者的治疗：聚焦因不良事件导致的TKI停药——总是更好就好吗？
Expert Rev Hematol. 2017 Jul;10(7):583-586. doi: 10.1080/17474086.2017.1339599. Epub 2017 Jun 13.
8
Long-Term Outcomes of Imatinib Treatment for Chronic Myeloid Leukemia.伊马替尼治疗慢性髓性白血病的长期疗效
N Engl J Med. 2017 Mar 9;376(10):917-927. doi: 10.1056/NEJMoa1609324.
9
Treatment-free remission following frontline nilotinib in patients with chronic myeloid leukemia in chronic phase: results from the ENESTfreedom study.慢性期慢性髓性白血病患者一线使用尼洛替尼后无治疗缓解：ENESTfreedom研究结果
Leukemia. 2017 Jul;31(7):1525-1531. doi: 10.1038/leu.2017.63. Epub 2017 Feb 20.
10
Deep molecular responses for treatment-free remission in chronic myeloid leukemia.慢性髓性白血病无治疗缓解的深度分子反应
Cancer Med. 2016 Sep;5(9):2398-411. doi: 10.1002/cam4.801. Epub 2016 Jul 1.